# Kidney–Lung Crosstalk in Acute Nephrologic Involvement: Mechanisms, Complement Activation, and Implications for Multiorgan Dysfunction

**Authors:** Giuliana Martino, Francesca Tinti, Marco Alfonso Perrone, Stefano Condò, Veronica Castagnola, Simone Manca de Villahermosa, Paola Triggianese, Marzena Olesinska, Alessandra Valentini, Sergio Bernardini, David Della Morte, Ferdinando Iellamo, Luca Salomone, Silvia Lai, Anna Paola Mitterhofer

PMC · DOI: 10.3390/life16020276 · 2026-02-05

## TL;DR

Acute kidney injury affects the lungs and other organs early on, highlighting the need for a systemic approach to diagnosis and treatment.

## Contribution

This study integrates real-world non-ICU data with experimental evidence to show kidney–lung crosstalk in early-stage AKI.

## Key findings

- Pulmonary involvement was present in 63% of AKI patients at hospital admission.
- AKI stage 1 was less common in patients with pulmonary involvement compared to those without.
- Complement activation is identified as a central amplifier of multiorgan dysfunction in AKI.

## Abstract

Acute kidney injury (AKI) is a systemic syndrome capable of inducing remote organ dysfunction. Kidney–lung crosstalk is a form of interorgan communication in acute nephrology, with the heart acting as a pivotal intermediary. Emerging evidence supports the involvement of a gut–lung–kidney axis. Complement activation in these multiorgan crosstalk has emerged as a central amplifier of multiorgan damage. We reviewed the literature on kidney–lung interactions and complement activation in AKI through a bibliographic search of PubMed, Scopus, and Web of Science. Most available data derive from experimental studies or intensive care unit (ICU) populations, often reported in reviews. We further report our real-world experience in a non-ICU nephrology setting, including 186 consecutive patients with AKI. Pulmonary involvement was present at hospital admission in 118 patients (63%). AKI stage 1 was observed in 20/118 patients (17%) with pulmonary involvement compared with 18/68 patients (27%) without pulmonary involvement (p < 0.001). In conclusion, AKI should be regarded as a systemic disease from its earliest stages. Kidney–lung interactions are clinically relevant even in mild AKI and outside critical care settings, underscoring the need for integrated organ assessment in routine nephrology practice. This review integrates complement activation as a central amplifier of kidney–lung crosstalk and multiorgan dysfunction, bridging experimental evidence with real-world observations from a non-critical care AKI population. By focusing on early AKI stages and the timing of pulmonary involvement, we highlight AKI as an active driver of systemic organ interactions rather than a late consequence of critical illness.

## Linked entities

- **Diseases:** acute kidney injury (MONDO:0002492), AKI (MONDO:0002492)

## Full-text entities

- **Genes:** CLU (clusterin) [NCBI Gene 1191] {aka AAG4, APO-J, APOJ, CLI, CLU1, CLU2}, MPO (myeloperoxidase) [NCBI Gene 4353], Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, AVP (arginine vasopressin) [NCBI Gene 551] {aka ADH, ARVP, AVP-NPII, AVRP, VP}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD55 (CD55 molecule (Cromer blood group)) [NCBI Gene 1604] {aka CHAPLE, CR, CROM, DAF, TC}, CD59 (CD59 molecule (CD59 blood group)) [NCBI Gene 966] {aka 16.3A5, 1F5, EJ16, EJ30, EL32, G344}, C5AR1 (complement C5a receptor 1) [NCBI Gene 728] {aka C5A, C5AR, C5R1, CD88}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, SERPING1 (serpin family G member 1) [NCBI Gene 710] {aka C1IN, C1INH, C1NH, HAE1, HAE2}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, CR1 (complement C3b/C4b receptor 1 (Knops blood group)) [NCBI Gene 1378] {aka C3BR, C4BR, CD35, KN}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, ELANE (elastase, neutrophil expressed) [NCBI Gene 1991] {aka ELA2, GE, HLE, HNE, NE, PMN-E}, CD46 (CD46 molecule) [NCBI Gene 4179] {aka AHUS2, MCP, MIC10, TLX, TRA2.10}, MBL2 (mannose binding lectin 2) [NCBI Gene 4153] {aka COLEC1, HSMBPC, MBL, MBL2D, MBP, MBP-C}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, C5ar1 (complement component 5a receptor 1) [NCBI Gene 12273] {aka C5aR, C5r1, Cd88, D7Msu1}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, C4BPA (complement component 4 binding protein alpha) [NCBI Gene 722] {aka C4BP, PRP}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, C3AR1 (complement C3a receptor 1) [NCBI Gene 719] {aka AZ3B, C3AR, HNFAG09}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, CFH (complement factor H) [NCBI Gene 3075] {aka AHUS1, AMBP1, ARMD4, ARMS1, CFHL3, FH}
- **Diseases:** ischemic injury (MESH:D017202), cardiovascular remodeling (MESH:D002318), CKD (MESH:D012080), congestion (MESH:D002311), infection (MESH:D007239), vascular remodelling (MESH:D066253), Right ventricular dysfunction (MESH:D018497), Uremic (MESH:D006463), interstitial (MESH:D065167), renal involvement (MESH:C565423), tachypnea (MESH:D059246), cytotoxic (MESH:D064420), vascular dysfunction (MESH:D002561), endothelial injury (MESH:D057772), IRI (MESH:D015427), epithelial (MESH:D009375), microvascular (MESH:D017566), Renal tubular injury (MESH:D015499), pulmonary congestion (MESH:D001261), cardiorenal-pulmonary syndrome (MESH:D059347), renal sodium retention (MESH:D016055), neutrophilia (MESH:C563010), Complement (MESH:D007153), neutrophil (MESH:C564275), acute organ injury (MESH:D001930), septic (MESH:D001170), complement dysregulation (OMIM:614878), DAMP (MESH:D000081030), exchange (MESH:D001816), Bidirectional Dysfunction (MESH:C535438), sepsis (MESH:D018805), pulmonary hypertension (MESH:D006976), tissue injury (MESH:D017695), extra-renal complications (MESH:D007674), Cardiac congestion (MESH:D006331), systemic (MESH:D015619), postoperative (MESH:D019106), impaired gas exchange (MESH:D011007), tubular damage (MESH:D000230), endothelial dysfunction (MESH:D014652), Lung Dysfunction (MESH:D008171), ischemic (MESH:D002545), Dysbiosis (MESH:D064806), dyspnea (MESH:D004417), nephron injury (MESH:D007683), VILI (MESH:D055397), kidney failure (MESH:D051437), alveolar damage (MESH:D055370), Renal tubular epithelial injury (MESH:D002277), chronic kidney disease (MESH:D051436), edema (MESH:D004487), pulmonary edema (MESH:D011654), ALI (MESH:D055371), Metabolic disturbances (MESH:D024821), critical illness (MESH:D016638), Pulmonary involvement (MESH:C566343), fibrosis (MESH:D005355), volume overload (MESH:D019190), Inflammatory (MESH:D007249), uremia (MESH:D014511)
- **Chemicals:** natriuretic peptides (MESH:D045265), bicarbonate (MESH:D001639), organic acids (-), indoxyl sulfate (MESH:D007200), sodium (MESH:D012964), hydrogen ion (MESH:D011522), ROS (MESH:D017382), calcium (MESH:D002118), creatinine (MESH:D003404), ATP (MESH:D000255), lipopolysaccharides (MESH:D008070), prostaglandins (MESH:D011453), p-cresyl sulfate (MESH:C408690), lactate (MESH:D019344), carbon (MESH:D002244), aldosterone (MESH:D000450), Oxygen (MESH:D010100), adenine (MESH:D000225), nitric oxide (MESH:D009569), nicotinamide (MESH:D009536), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941840/full.md

---
Source: https://tomesphere.com/paper/PMC12941840